Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742788 | 0.88 | KDM4E (0.58) | CYP3A4CYP1A2CYP2D6L3MBTL1BLM | |
| SCHEMBL1025521 | 0.81 | ALOX5 (0.52) | AOC3ALDH1A1LDHASMN1; SMN2 | |
| SCHEMBL1029848 | 0.79 | AOC3 (0.55) | CYP1A2AOC3MEN1KMT2A | |
| SCHEMBL14679320 | 0.77 | CYP3A4 (0.60) | CYP3A4CYP1A2CYP2D6L3MBTL1BLM | |
| SCHEMBL22068716 | 0.77 | L3MBTL1 (0.36) | CYP3A4CYP2D6L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5464541 | 0.76 | ALDH1A1 (0.49) | CYP3A4CYP1A2CYP2D6L3MBTL1BLM | |
| SCHEMBL1026318 | 0.75 | AOC3 (0.53) | CYP3A4CYP1A2CYP2D6AOC3ALDH1A1 | |
| SCHEMBL2881402 | 0.75 | PPARA (0.49) | L3MBTL1ALDH1A1MEN1KMT2ACA12 | |
| SCHEMBL1027884 | 0.75 | MEN1 (0.47) | CYP1A2L3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4147783 | 0.75 | ESRRG (0.49) | L3MBTL1BLMALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278440-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-02 | — | — | US | disclosed |
| US-20110201805-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201805-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | CYP3A4 15/4885CYP1A2 19/4885CYP2D6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.